https://www.selleckchem.com/pr....oducts/ndi-091143.ht
6-fold in ≥ 15-year survivors (95% CI = 3.0 to 4.1). Primary disease accounted for 50% of deaths in the overall cohort, and only 10% in 15-year survivors; the leading causes of non-disease-related mortality were subsequent malignancy (26.1%) and cardiopulmonary diseases (20.2%). We also identified the risk factors for non-disease-related mortality in 1- and 5-year survivors. CONCLUSION Survival probability improves the longer patients survive after HCT. However, HCT recipients surviving ≥15 years remain at elevated mortality risk, la
Like
Comment
Share
